Articles related to ASPIRIN

In this randomized trial of 1,010 patients with stable DES undergoing noncardiac surgery, perioperative aspirin continuation showed no significant reduction in major adverse cardiac events compared to complete antiplatelet cessation.

Recent survey findings reveal that nearly one-third of adults aged 60 and older take daily aspirin for primary prevention of heart disease, despite updated guidelines advising against it for those without prior cardiovascular events.

In this pivotal trial, apixaban, when used for subclinical atrial fibrillation, demonstrated a 0.63 hazard ratio for stroke or systemic embolism compared to aspirin, indicating a significant reduction in stroke risk at the expense of increased bleeding risk.

Recent research reveals aspirin’s significant impact on reducing cancer mortality and preventing metastatic spread, offering a promising addition to cancer therapy protocols.